scholarly journals SKIN-CAP IN THE TREATMENT OF CHRONIC DERMATOSES.Medica l Techno logy

2010 ◽  
Vol 7 (1) ◽  
pp. 66-70
Author(s):  
L F Znamenskaya ◽  
T A Goryacheva ◽  
S V Yakovleva ◽  
N V Kungurov ◽  
M M Kokhan ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Events ◽  
Medical Technology ◽  
Clinical Presentation ◽  
Combined Therapy ◽  
Therapeutic Action ◽  
Fungal Contamination ◽  
Treatment Algorithms

This Medical Technology summarizes therapeutic action and treatment algorithms of Skin-Cap in atopic dermatitis management depending on clinical presentation, stage and adverse events. Skin-cap as a part of the combined therapy decreases microbial and fungal contamination of the skin and minimizes other very active agents usage. The licence for it's administration is available at www.roszdravnadzor.ru

Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy

Dermatology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Niccolò Gori ◽  
Andrea Chiricozzi ◽  
Dalma Malvaso ◽  
Dario Francesco D’Urso ◽  
Giacomo Caldarola ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Adverse Events ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Real Life ◽  
Signs And Symptoms ◽  
Severe Atopic Dermatitis ◽  
Inadequate Response ◽  
Conventional Drug ◽  
Systemic Agents

<b><i>Background:</i></b> Dupilumab, a monoclonal antibody inhibiting the signaling pathway of IL-4/IL-13, was shown to be safe and effective in the treatment of moderate/severe atopic dermatitis (AD) in several clinical trials and real-life experiences, with only a small percentage of patients showing to be resistant or to lose disease control. <b><i>Objectives:</i></b> In this study, we investigated the effectiveness and safety in combining dupilumab with systemic agents or phototherapy in patients experiencing an inadequate response to dupilumab. <b><i>Methods:</i></b> This retrospective, monocentric, observational study consecutively included patients aged &#x3e;18 years, with moderate-severe AD, under treatment with dupilumab. In this cohort of patients, we analyzed data of subjects who experienced an inadequate response to dupilumab, even when combined with topical corticosteroids, and for whom an additional systemic treatment or phototherapy was combined to dupilumab. <b><i>Results:</i></b> In this study, we included a total population of 69 patients treated with dupilumab. In 12/69 patients (17.4%) showing an inadequate response to dupilumab, a combined treatment consisting of dupilumab plus methylprednisolone (<i>n</i> = 5), cyclosporine (<i>n</i> = 4), methotrexate (<i>n</i> = 2), or narrow band-UVB (<i>n</i> = 1) was administered. Overall, after 8 weeks of combined therapy, the majority of patients (11 of 12) obtained an improvement of signs and symptoms of AD. Patients treated with combined therapy did not experience any adverse events, neither did they withdraw treatment because of the occurrence of adverse events. <b><i>Conclusions:</i></b> This study suggests that the combination of dupilumab with a conventional drug or phototherapy may represent a valid therapeutic choice, maintaining a good safety profile in AD patients recalcitrant to dupilumab monotherapy.

Effectiveness of probiotics in combined therapy of atopic dermatitis

2017 ◽  
pp. 77-80
Author(s):  
S.M. Nedelska ◽  
◽  
O.D. Kuznietsova ◽  
O.O. Shevchenko ◽  
I.A. Kizilova ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Combined Therapy

scholarly journals Actinic reticuloid: case report

2019 ◽  
Vol 94 (6) ◽  
pp. 37-41
Author(s):  
E. V. Sokolovskiy ◽  
G. N. Mikheev ◽  
E. I. Demidova
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
T Cell ◽  
Ultraviolet Radiation ◽  
Nicotinic Acid ◽  
Treatment Effect ◽  
Clinical Presentation ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cytostatic Treatment

This article is about the case of actinic reticuloid — the rare dermatosis which clinical presentation is similar to atopic dermatitis, T-cell lymphoma. Good treatment effect was obtained by long cycles (2 cycles for 3 months) of hydroxychloroquine and sun protective therapy included sunscreens SPF 50, nicotinic acid, sun-safe clothes which blocked ultraviolet radiation without any glucocorticosteroid drugs and cytostatic treatment.

scholarly journals Efficacy of Three Different Prophylactic Treatments for Postoperative Nausea and Vomiting after Vitrectomy: A Randomized Clinical Trial

2019 ◽  
Vol 8 (3) ◽  
pp. 391 ◽  
Author(s):  
Michele Reibaldi ◽  
Matteo Fallico ◽  
Antonio Longo ◽  
Teresio Avitabile ◽  
Marinella Astuto ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Postoperative Pain ◽  
Adverse Events ◽  
Local Anesthesia ◽  
Postoperative Nausea ◽  
Therapy Group ◽  
Combined Therapy ◽  
Postoperative Nausea And Vomiting ◽  
Nausea And Vomiting ◽  
Combination Group

Postoperative nausea and vomiting (PONV) after vitreoretinal surgery may potentially be associated with severe complications, such as suprachoroidal hemorrhage. The purpose of the present multicenter clinical trial (NCT02386059) was to assess the efficacy of three different prophylactic treatments for PONV after vitrectomy under local anesthesia. Patients undergoing primary vitrectomy were randomized to the control arm or to one of the treatment arms (4 mg ondansetron, 4 mg dexamethasone, combination of the two drugs). The primary outcome measure was the proportion of complete response (no nausea, no vomiting, no retching, and no use of antiemetic rescue medication) during 24 h after vitrectomy. Secondary outcomes included the severity standardized score of PONV, postoperative pain standardized score, and rate of ocular and non-ocular adverse events. Baseline demographics of the 1287 patients were comparable between the four arms. The combined therapy group showed a statistically significant lower incidence of PONV compared to the placebo and monotherapy (p < 0.001). PONV severity was also reduced in the combination group compared to the others (p < 0.001). Postoperative pain scores and adverse events were comparable among the four groups. Combined therapy with dexamethasone and ondansetron was the most effective treatment for reducing the incidence and severity of PONV in patients undergoing vitrectomy under local anesthesia.

scholarly journals Clinical Presentation of Atopic Dermatitis by Filaggrin Gene Mutation Status during the First 7 Years of Life in a Prospective Cohort Study

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e48678 ◽  
Author(s):  
Charlotte Giwercman Carson ◽  
Morten Arendt Rasmussen ◽  
Jacob P. Thyssen ◽  
Torkil Menné ◽  
Hans Bisgaard
Keyword(s):  
Atopic Dermatitis ◽  
Cohort Study ◽  
Gene Mutation ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Clinical Presentation ◽  
Mutation Status

Efficacy and Safety of Orally Administered Lentinula edodes Mycelia Extract for Patients Undergoing Cancer Chemotherapy: A Pilot Study

2011 ◽  
Vol 39 (03) ◽  
pp. 451-459 ◽  
Author(s):  
Yoshiyuki Yamaguchi ◽  
Eiji Miyahara ◽  
Jun Hihara
Keyword(s):  
Adverse Events ◽  
Cancer Chemotherapy ◽  
Gastrointestinal Cancer ◽  
Large Scale ◽  
Lentinula Edodes ◽  
Nk Cell ◽  
Combined Therapy ◽  
Cell Activity ◽  
Concomitant Administration ◽  
Immunosuppressive Acidic Protein

Lentinula edodes mycelia extract (L.E.M.) is extensively utilized as an herbal medicine. However, its safety and effectiveness have not yet been scientifically verified. In this study, we investigated its safety and its influence on quality of life (QOL) and the immune response in patients undergoing cancer chemotherapy. Seven patients were studied in total. The patients were undergoing postoperative adjuvant chemotherapy for breast cancer (n = 3) or gastrointestinal cancer (n = 2), or were receiving chemotherapy to prevent recurrence of gastrointestinal cancer (n = 2). The first course of treatment was chemotherapy alone and the second was chemotherapy plus concomitant administration of L.E.M. Adverse events and changes in the QOL score, lymphocyte subpopulations, lymphocyte activity and serum immune indices were evaluated during the study period. No adverse events attributable to L.E.M. were observed. Compared to the pre-chemotherapy state, no changes in QOL or immune parameters were noted after the first chemotherapy course. In contrast, following the second course of combined therapy, improvements were noted in QOL (p < 0.05), NK cell activity (p < 0.05) and immunosuppressive acidic protein (IAP) (p < 0.01) levels. Although a future large-scale investigation is necessary to confirm these results, these data suggest that the concomitant of L.E.M. with chemotherapy is safe and improves the QOL and immune function of patients undergoing chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document